Liver metastases are common in gastroenteropancreatic neuroendocrine tumors and significantly impair survival. Hepatic resection is the only potential curative treatment. The records of 41 consecutive patients undergoing exhaustive resection of liver-only endocrine metastases and followed between 1992 and 2006 were reviewed. Patient's outcome and diagnostic accuracy of somatostatin receptor scintigraphy (SRS) and morphological imaging (MI) for detection of recurrences during post-operative follow-up were assessed. All identified primary had been resected. MI studies including abdominal computed tomography (CT) and/or liver magnetic resonance imaging and thoracic CT if indicated were performed every 6 months; SRS timing was decided by referring clinician. Tumor recurrences were confirmed by pathology or subsequent imaging studies. The results of 136 MI and SRS examinations performed within a 30-day interval from each other were retrospectively compared. Median post-operative follow-up was 51 months (7-165). Recurrences developed in 32 patients (78%), mainly in the liver (nZ24) after a median of 19 months (2-79). Five-year overall and disease-free survival rates were 79 and 3% respectively. For recurrence detection, sensitivity, specificity, and accuracy were 89, 94, and 91% for SRS, 68, 91, and 74% for MI respectively. In 11 out of 32 patients (34%), abdominal or extra-abdominal metastases were detected 15.5 months earlier by SRS than MI. In conclusion, despite exhaustive liver surgery for endocrine metastases, hepatic or extra-hepatic recurrences are frequent and develop early. SRS is highly accurate for the detection of recurrences during post-operative follow-up and permitted early diagnosis in one third of patients; therapeutic implications of this early diagnosis remain to be determined.
Introduction
Among patients with gastroenteropancreatic neuroendocrine tumors (GEPNET), 30-80% present with synchronous or metachronous liver metastases (Moertel 1987 , Mignon 2000 . The presence and extent of hepatic metastases are the most pejorative prognostic determinants (Moertel 1987 , Madeira et al. 1998 , Steinmüller et al. 2008 . For patients with carcinoid tumors, overall 5-year survival rates are 70-80 and 50% when liver metastases are absent or present respectively (Janson et al. 1997) . Patients with resected gastrinomas have overall 5-year survival rates of 65-100% when the liver is free of disease, and below 30% when liver metastases are present (Weber et al. 1995 , Yu et al. 1999 , Mignon 2000 .
Management of patients with liver metastases is heterogeneous and includes loco-regional procedures (liver surgery, orthotopic liver transplantation, sequential hepatic artery embolization, trans-arterial chemoembolization, and radiofrequency ablation), systemic procedures (chemotherapy and somatostatin receptor radionuclide therapy), and symptomatic medical treatment of the secretory syndrome. But surgery is the only potential curative treatment (Norton 2005 , Plöckinger & Wiedenmann 2005 when complete resection (R0 resection) of all primary tumor and visible liver lesions can be performed, before metastatic spread to local or distant sites occurs. In recent years, aggressive liver surgery for locally advanced and metastatic GEPNET has been proposed, in order to improve duration and quality of life (Que et al. 1995 , Chen et al. 1998 , Frilling et al. 1998 , Ahlman et al. 2000 , Chamberlain et al. 2000 , Sarmiento et al. 2002 , 2003 , Elias et al. 2003 , Norton et al. 2003 .
Imaging studies play an important role in the preand post-operative management of patients with GEPNET. Morphological imaging (MI) techniques such as computed tomography (CT), ultrasonography (US), and magnetic resonance imaging (MRI) are the basic imaging methods for diagnosis and assessment of treatment response. Functional imaging with somatostatin receptor scintigraphy (SRS), which relies on the use of 111 In-DTPA-octreotide, a radiolabeled somatostatin analog, allows in vivo visualization of the cell-surface somatostatin receptors (mainly subtype 2) expressed by most GEPNET (Reubi et al. 1987 , 1990 , 2000 , John et al. 1996 . SRS has been shown to be an effective screening test for initial localization and staging of GEPNET (Plöckinger & Wiedenmann 2005) .
The purpose of this study was to retrospectively analyse the outcome of 41 consecutive patients with GEPNET after exhaustive hepatic surgery for liver metastases as a 15-year experience in a single institution, and to evaluate the respective diagnostic values of MI and SRS studies to identify hepatic and extra-hepatic recurrences during follow-up.
Materials and methods

Patient population
The records of 41 consecutive patients with histologically proven GEPNET, followed between 1992 and 2006 at the Gastroenterology Department of Beaujon University Hospital and who underwent liver surgery with curative intent for synchronous (nZ30) or metachronous (nZ11) metastases, were retrospectively reviewed (Table 1) . There were 25 women (61%) and 16 men (39%). Median age at diagnosis was 51 years F, female; M, male; s or m, synchronous or metachronous liver metastases; N, non-functioning GEPNET; NA, not available; Adj Ch, adjuvant chemotherapy (C, combination of streptozotocin and 5-fluorouracil); d, dead of disease (the patient died x months after hepatectomy, and had y distinct tumor recurrences after hepatectomy); a, alive (the patient had x distinct tumor recurrences after hepatectomy); l, lost to follow-up (the patient was lost to follow-up x months after hepatectomy, and had y distinct tumor recurrences after hepatectomy). (range: 21-75). Median duration of follow-up from hepatectomy was 51 months (range: 7-165 months). Five patients were lost during follow-up, 11-52 months (median: 38 months) after liver surgery. All diagnoses were confirmed and characterized according to the World Health Organization criteria (Solcia et al. 2000 , Klöppel et al. 2004 . Twenty-five patients (61%) had non-functioning and 16 (39%) had functioning tumors, including gastrinomas (nZ7 patients), carcinoid tumors (nZ6), vipoma (nZ1), insulinoma (nZ1), and glucagonoma (nZ1). Primary tumors were mainly located in the pancreas (nZ17 patients, 41%) and in the small intestine, duodenum excluded (nZ13, 29%). Other sites were the duodenum (nZ2), the proximal colon (nZ1), the rectum (nZ1), abdominal lymph nodes (nZ2), and the stomach (nZ1). In 4 out of 41 patients (10%), the primary tumor remained undetected despite thorough pre-operative imaging studies and meticulous intra-operative exploration. No patient had a multiple endocrine neoplasia syndrome. Tumor differentiation was good, moderate, or poor in 76, 17, and 7% of patients respectively.
Aggressive liver surgery was decided during multidisciplinary meetings for patients fulfilling the following criteria: 1) completely resected (or resectable) primary tumor, except if the primary was unknown; 2) no peritoneal carcinomatosis and no extrahepatic metastases; 3) complete resection of all liver metastases seemed technically possible without compromising liver function; 4) good performance status index and no major comorbidity. Pre-operative imaging work-up included CT of the thorax, abdomen and pelvis, upper and lower digestive endoscopy, as well as SRS to assess the presence or absence of hepatic and extrahepatic metastases. Liver MRI was part of pre-operative investigations in recent years (10 patients). Endoscopic US was obtained for GEPNET located in the duodenum or the pancreas. Intra-operative US was systematically performed to evaluate the liver parenchyma.
All identified primary tumors (as well as regional lymph nodes) were completely removed, either prior to, at the time of, or after liver surgery in 16, 20, and 1 patient(s) respectively. Liver metastases had a median size of 10 mm (range: 2-170 mm). Twenty-eight (68%) patients had bilateral liver involvement and 19 (46%) patients had at least ten liver metastases. Liver surgical procedures included tumorectomy (nZ6 patients, 15%), segmentectomy (nZ1, 2%), left hepatectomy (nZ7, 17%) associated with concomitant right liver tumorectomy in four patients, right hepatectomy (nZ8, 20%) associated with concomitant left liver tumorectomy in three patients, two-stage hepatectomy (nZ14, 34%) performed as previously reported (Kianmanesh et al. 2005 , Steinmüller et al. 2008 , and liver transplantation (nZ5, 12%). For three patients, liver surgery was combined with tumor destruction with alcohol injection for tumors too deep to be resected (one, two, and three tumors respectively). Twenty patients had post-operative (adjuvant) systemic chemotherapy. Patients were considered for adjuvant chemotherapy during multidisciplinary oncologic meetings 1) if the primary tumor was pancreaticin patients with non-pancreatic primary tumors, adjuvant chemotherapy was indicated in patients less than 50 years old or patients with at least ten liver lesions or after liver transplantation; 2) provided uneventful post-operative course so that chemotherapy could start within 6 weeks after surgery; 3) if the patients had normal biological data; and 4) if they gave their informed consent. Adjuvant chemotherapy included four cycles of i.v. streptozotocin-5-fluorouracil: 500 and 400 mg/m 2 respectively daily for 5 days every 42 days (Maire et al. 2009 ).
Methods
After liver surgery, systematic follow-up was based on clinical and symptom evaluation, biology (general and specific endocrine markers), and MI studies (abdominal CT and/or liver MRI, thoracic CT when indicated) every 6 months (G1 month). Timing of SRS studies was left to the appreciation of the referring clinician; 27 out of 41 patients underwent systematic SRS studies on a yearly basis. Imaging evaluations could be performed earlier depending on previous clinical, biological, or imaging findings. Consensus about disease status and therapeutic management was reached for each patient during multidisciplinary meetings, on the basis of all available information.
Imaging techniques
Unenhanced and contrast-enhanced abdominal and pelvic CT and, when indicated, thoracic CT were obtained. Between 1992 and 1996, CT studies were performed with a conventional scanner (Somatom DRG1, Siemens, Erlangen, Germany). Unenhanced and contrast-enhanced scans were performed. Nonionic-iodinated contrast material (300 mg of iodine per milliliter) was administered i.v. with a power injector. A 60 ml bolus (2 ml/s) was first injected, followed by a 100 ml infusion (1 ml/s) during data acquisition. Abdominal imaging included two sets of 5-mm-thick sections, the first set started 35-40 s after the initiation of injection, and the second set immediately after. Liver imaging was completed within 2 min. Oral contrast material was given. Between 1996 and 2001, CT examinations were performed with a helical scanner (CT Twin, Elscint, Haïfa, Israël). Helical CT images were obtained before and after a monophasic injection of 140 ml of non-ionic-iodinated contrast material (350 mg of iodine per ml) at a rate of 2 ml/s. For abdominal imaging, three sequential breath-hold helical acquisitions were performed: during the hepatic arterial phase (acquisition through the whole liver, collimation: 5 mm; pitch: 1.5), the pancreatic phase (acquisition through the whole pancreas, collimation: 2.5 mm; pitch: 1.5), and the portal venous phase (acquisition through the whole liver and pancreas, collimation: 5 mm; pitch: 1.5) at 30, 45, and 70 s respectively, after the initiation of contrast injection. In most cases, oral contrast material was not given, but water was given to obtain complete filling of the duodenal lumen. Since 2001, a Light Speed Ultra spiral scanner (General Electric Medical Systems, Milwaukee, WI, USA) was used. Helical CT images were obtained before and after a monophasic injection of 100-120 ml of non-ionic-iodinated contrast material (350 mg of iodine per ml) at a rate of 3 ml/s. Sequential breath-hold helical acquisitions (collimation: 1.25 mm) were performed during the hepatic arterial phase (reconstructed section thickness: 5 mm; pitch: 0.875), the pancreatic phase (reconstructed section thickness: 2.5 mm; pitch: 0.875), and the portal venous phase (reconstructed section thickness: 5 mm; pitch: 0.875) at 30, 45, and 70 s respectively, after the initiation of contrast injection. Ingestion of water was obtained.
Liver MRI was done routinely only in recent years, in 16 patients (22 studies). MRI studies were performed with a 1.5-Tesla system (Gyroscan Intera, Philips Medical Systems, Best, The Netherlands) by using a phased-array torso coil for signal reception. Sequences included a breath-hold T1-weighted fast-field echo, a respiratory-triggered T2-weighted fast-spin echo; T1-weighted imaging was repeated during the hepatic arterial (20-25 s delay), portal venous (60-70 s delay), and delayed (5-10 min delay) phases after administration of gadolinium-based contrast medium (Dotarem, Guerbet, France) at a dose of 0.1 mmol/kg (Vilgrain 2003 , Lewin et al. 2006 . SRS studies were performed after i.v. injection of 185 MBq 111 In-pentetreotide (Octreoscan, Mallinckrodt Medical, Petten, The Netherlands) containing 10 mg somatostatin analog. The specific radiochemical purity was checked by chromatography (O95%). Scintigraphic planar images covering the wholebody (4, 24, and G48 h after injection) and abdominal single-photon emission-computed tomography (24 h after injection) were acquired using a double-head gamma camera with a medium-resolution parallel-hole collimator, as previously reported (Lebtahi et al. 2002) .
All MI studies were performed at the Radiology department and all but eight SRS studies at the Nuclear Medicine department at our institution.
Data analysis
All radiological and scintigraphic images (whether or not performed at our institution) had been individually interpreted at the time of their performance by radiologists or nuclear medicine physicians respectively with strong experience in endocrine tumor imaging. In the retrospective review, we considered all SRS and MI (CT and/or liver MRI) examinations that were performed during post-operative follow-up within a 30-day interval from each other. One hundred and thirty-six imaging explorations met this criterion and were compared. Clinical reports generated at the time of MI or SRS studies were used in the data analysis. All reported lesions were translated into 'recurrence' or 'no recurrence' both for MI and SRS studies: all lesions classified as suspicious of GEPNET recurrence were considered recurrence and lesions reported as probably benign were considered no recurrence, there were no 'indeterminate' interpretations. Histological and/or imaging follow-up findings were used as gold standards: recurrent disease was confirmed in all patients by histological examination and/or by an obvious progression in the number and/or size of the lesions on subsequent imaging studies.
Statistical analysis
For each patient, survival was calculated from the time of hepatectomy. Survival probabilities were calculated by the Kaplan-Meier method, univariate analysis of survival rates was performed using the log-rank test for categorical variables. A P value of 0.05 was considered indicative of a statistically significant difference. Continuous variables are shown as median and range. Imaging data are presented with 95% confidence intervals.
Results
Morbidity-mortality of liver surgery
There were no perioperative deaths; 7 out of 41 patients (17%) had one or more complications with favourable outcome (pulmonary embolism, nZ3; bile fistula, nZ1; intra-abdominal abscess, nZ1; pleural effusion, nZ1; ascitis, nZ2; mild and transient hepatic insufficiency, nZ1; bile leak, nZ1).
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Completeness of surgery
All identified primary tumors (37 patients) were macroscopically completely removed. Surgical margins were histologically negative (R0 resection) in 34 patients (92%) and positive (R1 resection) in 3. Microscopic tumor remnant was observed on the pancreatic section in two patients (one of them was reoperated on to obtain a negative histological margin) and in the third patient on the section margin of a tumor mass corresponding to a primary tumor of the ileum with nodal involvement.
Thirty-seven patients (90%) had a complete macroscopic resection (R0, nZ26 patients (63%); R1, nZ11 (27%)) of the liver metastases (Table 1) ; the hepatic security margin ranged from 0 to 20 mm. Four patients (10%) had a R2 resection (residual macroscopic tumor; Table 1 ). In 20 out of 35 patients (57%; no data available for six patients), histological analysis reported the presence of microscopic tumor foci in the macroscopically normal liver and/or angioinvasion ( Table 1) .
Outcome of patients after exhaustive liver surgery
Median duration of post-operative follow-up was 51 months (range: 7-165). Nine patients (22%) remained disease free, whereas 32 patients (78%) developed tumor recurrence after a median of 19 months (range: 2-79; Table 1 ). Sites of this first recurrence are reported in Table 2 : liver (nZ24 patients), abdominal (nZ5) or thoracic (nZ2) lymph nodes, lung (nZ3), bone (nZ5), thyroid (nZ1), and/or s.c. tissue (nZ1). Out of 32 patients, 9 experienced at least another hepatic or extra-hepatic tumor recurrence that was accessible to diverse therapeutic options (Table 1) .
Out of 41 patients, 7 (17%) died from tumor progression, after a median of 47 months (range: 16-118) . No death occurred among the 9 out of 41 disease-free patients.
Overall survival (OS) was 95% at 3 years and 79% at 5 years (Fig. 1) . Disease-free survival (DFS) was 65% at 1 year, 25% at 3 years, and 3% at 5 years (Fig. 2) . Median OS had not been reached, median DFS was 20 months. Univariate analysis of factors potentially predictive of survival included tumor differentiation, endocrine activity, site of the primary (pancreatic or non-pancreatic origin), uni-or bilateral liver involvement, completeness of liver surgery, liver tumor mitotic index and proliferation marker Ki-67, and pathological factors of poor prognosis (intra-hepatic micrometastases and/or angioinvasion; Table 3 ). Only the presence of poor pathological factors reached statistical significance to predict OS (PZ0.05, Table 3 ). Early recurrence detection by imaging studies (prior to median recurrence time) did not influence OS (PZ0.11; Table 3 ). Adjuvant chemotherapy had no impact on recurrence: 16 out of 20 (80%) patients who had and 16 out of 21 (76%) who had no adjuvant chemotherapy experienced recurrences 2-79 months (median: 20.5) and 5-58 months (median: 12.5) after liver surgery respectively.
Repeated interventional procedures were indicated in 16 out of 24 patients who developed liver recurrences: hepatic reresectionGradiofrequency ablation (nZ12 patients, including two patients who received orthotopic liver transplantation); transarterial chemoembolization (nZ3); radiofrequency ablation (nZ1).
Out of the seven patients who underwent total hepatectomy with liver transplantation, recurrences occurred in four patients (57%) after a median of 23 months (range: 3-45) and exclusively outside the hepatic graft. The three disease-free-transplanted patients have a follow-up of 35, 35, and 38 months respectively.
Diagnostic values of SRS and MI to detect hepatic or extra-hepatic recurrences
During follow-up after hepatectomy, the 41 patients were investigated simultaneously by SRS and MI (i.e. when SRS and MI studies were performed within a 30-day interval from each other) in a total of 136 imaging examinations. MI examinations comprised 136 abdominalGthoracic CT and 22 liver MRI performed in 16 patients. SRS and MI studies were concordant in 87 out of 136 (64%) examinations: both methods showed no lesion in 36 out of 87 examinations Table 4 ; results differentiated for the various sites of tumor recurrence and for each imaging technique are reported in Table 5 . SRS had higher accuracy, sensitivity, and negative predictive value (NPV) than MI to detect tumor recurrence sites; their specificity and positive predictive value were similar. When considering all sites of tumor recurrence, in 11 out of 32 patients (34%) who recurred (25 examinations), SRS showed recurrences earlier than MI. Closer MI studies were then obtained and showed, in all patients, corresponding lesions with a median delay of 15.5 months (range 5-31 months). All cases of recurrence were confirmed by histological analysis and/or by progressive lesions on subsequent MI studies at sites previously abnormal on SRS. Recurrences were located in the liver (nZ5 patients; Fig. 3 ), abdominal or pelvic lymph nodes (nZ5), thoracic lymph nodes (nZ3; Fig. 4) , bone (nZ2), and/or pancreas (nZ1; Fig. 5 ).
When MI studies subsequently showed the lesions earlier detected by SRS, the size of corresponding lesions ranged from 7 to 22 mm for liver metastases, from !10 to 15 mm for abdominal or pelvic lymph nodes, and from 6 to 20 mm for thoracic lymph nodes. The median delay of detection of morphological abnormalities was 12, 12, 23, and 21 months for liver metastases, abdominal or pelvic lymph nodes, thoracic lymph nodes, and bone lesions respectively; the delay was 7 months for the pancreatic lesion. Conversely, MI identified tumor recurrences earlier than SRS in 2 out of 32 patients (6%): thoracic and abdominal CT showed lung involvement 3 months before lung abnormalities on SRS in one patient and abdominal enlarged lymph nodes 12 months before nodal foci of uptake on SRS in the second patient.
In 11 other patients (34%; 20 examinations), SRS revealed distant metastases that would otherwise have been ignored if only MI studies were performed: one pelvic recurrent mass (nZ1 patient), involvement of thyroid (nZ3), bone (nZ6), lung (nZ1), and/or thoracic lymph nodes (nZ3).
Discussion
Multiple independent studies have advocated aggressive surgical management of hepatic endocrine metastases. Such an approach was found to improve the quality of life in symptomatic patients (Que et al. 1995 , Chen et al. 1998 , Ahlman et al. 2000 , Chamberlain et al. 2000 , Sarmiento et al. 2003 , and was suggested to prolong survival: 5-year OS rates ranged from 71 to 85% for hepatectomized patients (Norton 2005) and from 20 to 30% for historical controls when liver metastases were neither resected nor ablated (Moertel 1987 , Chen et al. 1998 , Chamberlain et al. 2000 respectively. Surgical resection appears as the treatment of choice when all macroscopic primary tumor and liver metastases can be resected (Norton 2005 , Steinmüller et al. 2008 . In our series of 41 patients with liver-only metastases, hepatectomy was performed with curative intent and led to 3-and 5-year OS rates of 95 and 79% respectively with no operative death and low morbidity. These results are consistent with previous reports indicating that aggressive surgery for endocrine hepatic metastases is safely feasible by experienced surgeons in selected patients (Norton et al. 2003 , Sarmiento et al. 2003 . Whether such aggressive approach prolongs survival is, however, difficult to prove unequivocally. Because of the relatively low incidence of endocrine tumors, their markedly heterogeneous biological and clinical presentation, no randomized prospective trial has compared complete resection of liver metastases with no or other therapeutic options in rigorously comparable patients. Moreover, among studies, variable criteria are taken to select patients for liver surgery (liver tumor burden and the absence or presence of minimal extra-hepatic disease) making strict comparison of published survival rates difficult. However, in retrospective studies, a clear benefit of liver surgery was found by Chen et al. (1998) in 15 hepatectomized patients versus 23 non-resected patients (5-year OS of 73% and 29 respectively), and by Musunuru et al. (2006) in 13 hepatectomized patients versus 35 patients treated medically or by embolization (3-year OS of 83 and 31% respectively). In both studies, patient groups had similar tumor characteristics and percentage of liver involvement. At our institution, the general approach is to propose liver resection as the first-line treatment in patients with liver-only metastases in whom all primary had been completely removed or is potentially completely removable. Thus, we could not validly compare survivals of our hepatectomized with our nonhepatectomized patients who clearly had more extensive liver and/or extra-liver disease. However, the 5-year OS rate of 79% observed in our series compares favorably with the 5-year OS rate of 50% reported in 35 patients with tumor characteristics Intra-hepatic micrometastases and/or angioinvasion. close to ours and who were also highly selected (no peritoneal carcinomatosis and no extra-hepatic disease) before hepatectomy (Elias et al. 2003) . We report a very high recurrence rate: 3-and 5-year DFS were 25 and 3% respectively with a median time to recurrence of 19 months. As already observed, a minority of patients are cured after exhaustive hepatic surgery (Sarmiento et al. 2002 , 2003 , Elias et al. 2003 . Completeness of liver surgery is a major factor influencing development of recurrences (Nave et al. 2001 , Sarmiento et al. 2003 . Although, liver resection intended to be complete, 37% of our patients had micro or macroscopically incomplete liver surgery (R1 or R2 resection). Such discrepancy between exhaustive intent of liver surgery and effective results was previously noted by Elias et al. (2003) : only 53% of 47 highly selected patients had a R0 resection. Poor pathological factors (intra-hepatic micrometastases and/or angioinvasion) were present in 57% of our patients and were the only prognostic parameter found to have a significant impact on OS. All these data indicate that residual microscopic hepatic and/or extra-hepatic disease persists despite thorough pre-and intraoperative imaging explorations and exhaustive liver surgery. In this series, adjuvant chemotherapy did not influence the development of recurrence, as also recently reported in a dedicated study performed at our institution (Maire et al. 2009 ). This emphasizes the need for an efficient adjuvant therapy that could eradicate occult metastases and thus maximize the benefit of aggressive liver surgery. Perhaps, more targeted post-operative approaches could help to prevent or delay tumor recurrence after hepatic resection, such as somatostatin analogues (Norton 2005) , peptide receptor radionuclide therapy (Krenning et al. 1999 , Kwekkeboom et al. 2000 , and antiangiogenic drugs.
The second part of our study evaluated the usefulness of imaging studies to detect recurrences during follow-up. SRS has shown to be very sensitive and specific for the detection and staging of endocrine tumors and their hepatic and extra-hepatic metastases, both for functioning and non-functioning endocrine tumors (Scherubl et al. 1993 , Gibril et al. 1996 , Lebtahi et al. 1997 , Kwekkeboom et al. 2000 , Sundin et al. 2007 . Here, we focused on the respective values of SRS and MI studies to detect endocrine tumor recurrences during follow-up after liver surgery. SRS had significantly higher accuracy than MI, and particularly higher sensitivity and NPV. When differentiating results for various tumor sites, SRS also showed a significantly higher sensitivity for thoracic lymph nodes and bone lesions. Notably, SRS permitted to detect recurrences earlier than MI studies in 11 out of 32 patients (34%): SRS showed the disease as early as 31 months (median: 15.5 months, range: 5-31) before MI, both for hepatic and extrahepatic lesions. Recurrent tumors earlier detected by SRS were always apparent later on MI explorations, suggesting the precocity of functional versus morphological recurrence. MI defines disease states on the basis of macroscopic anatomical changes; functional imaging provides information on the biological In-DTPA-octreotide). (A) SRS showed one focus of uptake in the liver (white arrow) 9 years after initial surgery; abdominal CT and liver MRI were normal and no tumor recurrence was considered. (B) Seventeen months later, the focus of uptake was more intense (white arrow), an additional small focus appeared in the right liver (white arrowhead), abdominal CT was still normal; (C) Six months later, CT (C1, hepatic arterial phase after i.v. injection of contrast material) and MRI (C2, fast-spin echo fat-suppressed T2-weighted sequence) showed corresponding metastasis of 22 mm in the left liver. In-DTPA-octreotide). (A) SRS showed a focus of uptake above the liver (white arrow) 19 months after liver surgery; thoraco-abdominal CT was normal. (B) Six months later, the focus of uptake was more intense (white arrow), and thoracic-abdominal CT showed a corresponding supra-diaphragmatic nodular lesion (15 mm), that was then resected.
S Scigliano et al.: Clinical and imaging follow-up
www.endocrinology-journals.org processes (i.e. expression of somatostatin receptors by endocrine tumor cells) that may precede anatomical changes. Many of the lesions earlier detected by SRS were small (as small as 6 mm). The main explanation is that, although SRS has a limited spatial resolution (10 mm), smaller lesions can be detected due to their high density of somatostatin receptors (Plöckinger & Wiedenmann 2005) . This is particularly relevant for lymph nodes, because morphological criteria, mainly based on size, cannot distinguish with certainty all involved lymph nodes. Therapeutic implications of such early diagnosis of recurrence remain to be determined. In our series, early abnormal scintigraphic findings did not lead to immediate therapeutic decisions, but prompted the referring clinicians to obtain closer follow-up MI studies. Therapeutic management was then altered in all concerned patients, when subsequent MI depicted abnormalities corresponding to previously seen scintigraphic abnormalities. Early detection of abnormal nonphysiological foci of uptake on SRS studies without corresponding morphological lesion should lead to schedule closer MI evaluations during follow-up.
Our study has obvious limitations related to its retrospective design. First, imaging techniques continuously evolved during the study period and liver MRI was performed only in recent years. In the late 1990s, SRS was reported to be the single most sensitive imaging technique when compared with CT, MRI, US, and selective angiography to detect liver metastases from gastrinoma: SRS and MRI had a sensitivity of 92 and 71% respectively (Gibril et al. 1996) . In a recent study comparing SRS, MRI, and CT to detect endocrine liver metastases, MRI has been found to be the superior method; false-negative SRS results were mostly observed in cases of small metastases (Dromain et al. 2005) . The combined use of these two imaging techniques might achieve the most accurate disease evaluation for the liver. All imaging studies, both radiological and scintigraphic, had been performed according to the state of the art criteria of the moment. Liver endocrine metastases are hypervascular lesions supplied by the hepatic artery (Paulson et al. 1998 , Foley et al. 2000 . Their detection with MI requires thus acquisition during the hepatic arterial phase (starting 30 s after the beginning of contrast injection) when hypervascular tumors are hyperattenuating because they enhance more than the surrounding parenchyma (Foley et al. 2000 , Kopp et al. 2002 . Unenhanced contrast or portal venous phase (starting 60 s after the beginning of contrast injection) imaging alone can miss hypervascular lesions because they may appear iso or hypoattenuating (Patten et al. 1993 , Baron 1994 . During the arterial phase, 30% more endocrine liver metastases are found including 6% of metastatic patients exclusively evidenced during this phase (Paulson et al. 1998 ). In our institution, when patients had suspected or histologically proven Figure 5 A 58-year-old patient operated on for a pancreatic primary with synchronous liver metastases. SRS was performed during follow-up (anterior abdominal views and abdominal axial single-photon emission-computed tomography acquired 24 h after injection of 111 In-DTPA-octreotide). (A1 and A2) SRS showed one slight focus of uptake in the pancreatic area (white arrow) 23 months after liver surgery; abdominal CT was normal and showed one 15 mm lesion in the remnant pancreas 7 months later. The patient was followed with no therapeutic intervention. (B1 and B2) Eight months later, the pancreatic focus of uptake (white arrow) was evident and multiple hepatic metastatic foci appeared. (2009) 16 977-990 www.endocrinology-journals.org endocrine tumor, CT imaging protocols always included a hepatic arterial phase acquisition to ensure maximal detection of metastases in the liver. When slower CT scanning technology was used (before 1996), liver imaging encompassed both arterial and venous phases of contrast enhancement, consequently decreasing sensitivity to detect hepatic metastases compared with faster techniques using multislice helical CT (after 1996) . But this accounted for a minority of the examinations (3 out of 136) analyzed in this study. Second, only the original interpretation of SRS and MI studies was used in the analysis, and retrospective reinterpretation of the images was not included. Imaging studies were interpreted by either experienced radiologists or nuclear medicine physicians of the same institution. This study is thus the reflection of daily clinical practice in our institution serving as tertiary center for the management of patients with endocrine tumors.
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In conclusion, despite exhaustive liver surgery for endocrine tumor metastases, most patients will develop hepatic and/or extra-hepatic recurrences, rather early after liver surgery (median recurrence time of 19 months), suggesting that microscopic disease remains and should be the target of an efficient adjuvant therapy to enhance the benefit of surgery and prolong recurrence-free survival. SRS appears to be highly sensitive for the detection of recurrences during post-operative follow-up and seems to permit early diagnosis of recurrences in one third of patients.
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